Beam Therapeutics (NASDAQ:BEAM - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "sell" rating to a "strong sell" rating in a report released on Saturday, Wall Street Zen reports.
Other analysts have also recently issued reports about the stock. HC Wainwright reiterated a "buy" rating on shares of Beam Therapeutics in a research note on Tuesday. Weiss Ratings restated a "sell (d-)" rating on shares of Beam Therapeutics in a research report on Thursday, October 15th. Bank of America reaffirmed a "buy" rating and issued a $47.00 price target on shares of Beam Therapeutics in a report on Wednesday, July 8th. William Blair upgraded Beam Therapeutics to a "strong-buy" rating in a research report on Wednesday, September 23rd. Finally, Canaccord Genuity Group increased their price objective on Beam Therapeutics from $78.00 to $79.00 and gave the stock a "buy" rating in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Beam Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $46.90.
Read Our Latest Analysis on BEAM
Beam Therapeutics Stock Down 5.6%
Shares of Beam Therapeutics stock opened at $27.23 on Friday. Beam Therapeutics has a 12-month low of $20.23 and a 12-month high of $38.26. The company has a debt-to-equity ratio of 0.09, a current ratio of 14.57 and a quick ratio of 14.57. The company's 50-day moving average price is $25.93 and its 200-day moving average price is $28.19.
Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($1.18) EPS for the quarter, missing the consensus estimate of ($1.11) by ($0.07). The firm had revenue of $0.49 million for the quarter, compared to analysts' expectations of $16.37 million. Beam Therapeutics had a negative net margin of 54.75% and a negative return on equity of 30.71%. Beam Therapeutics's revenue was down 94.2% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.00) EPS. As a group, research analysts expect that Beam Therapeutics will post -4.49 earnings per share for the current year.
Insider Activity at Beam Therapeutics
In related news, CEO John Evans sold 25,000 shares of the company's stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $23.57, for a total value of $589,250.00. Following the transaction, the chief executive officer directly owned 1,047,205 shares in the company, valued at approximately $24,682,621.85. This represents a 2.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 3.80% of the company's stock.
Institutional Investors Weigh In On Beam Therapeutics
Several hedge funds have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. bought a new stake in Beam Therapeutics during the third quarter worth about $129,000. Profund Advisors LLC increased its position in shares of Beam Therapeutics by 10.0% during the 3rd quarter. Profund Advisors LLC now owns 52,359 shares of the company's stock valued at $1,280,000 after purchasing an additional 4,775 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Beam Therapeutics by 15.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 18,846 shares of the company's stock valued at $462,000 after purchasing an additional 2,473 shares during the last quarter. D.A. Davidson & CO. raised its holdings in shares of Beam Therapeutics by 5.0% during the 3rd quarter. D.A. Davidson & CO. now owns 105,697 shares of the company's stock valued at $2,584,000 after buying an additional 5,069 shares in the last quarter. Finally, Sterling Capital Management LLC raised its holdings in shares of Beam Therapeutics by 504.0% during the 3rd quarter. Sterling Capital Management LLC now owns 3,135 shares of the company's stock valued at $77,000 after buying an additional 2,616 shares in the last quarter. 99.68% of the stock is currently owned by institutional investors.
Beam Therapeutics News Summary
Here are the key news stories impacting Beam Therapeutics this week:
- Positive Sentiment: Clinical optimism remains a potential support. Beam reviewed initial Phase 1/2 data for BEAM-301 in glycogen storage disease type 1a, keeping investor attention on the company’s base-editing pipeline and future milestone potential. Beam Therapeutics reviews initial BEAM-301 data
- Positive Sentiment: Citi initiated or reiterated a Buy view on Beam, while broader healthcare commentary also identified BEAM among attractive stocks. This reinforces the bullish long-term case centered on gene editing and potential pipeline catalysts. Beam Therapeutics gets a Buy from Citi
- Positive Sentiment: Shares previously gained 15.6% on above-average volume, suggesting strong short-term interest. However, the accompanying analysis cautioned that recent earnings-estimate trends may not sustain the rally. Beam Therapeutics moves 15.6% higher
- Neutral Sentiment: Beam crossed above its 200-day moving average, a potentially constructive technical signal, but the report tied the move to an analyst downgrade, limiting its significance. Beam crosses above its 200-day moving average
- Negative Sentiment: Wedbush cut its price target, adding pressure to the stock after its recent advance. The downgrade signals more cautious near-term expectations even as other analysts remain constructive. Wedbush cuts Beam Therapeutics price target
- Negative Sentiment: HC Wainwright retained a Buy rating but lowered most 2026–2029 EPS forecasts, including FY2026 to a loss of $4.67 per share and FY2027 to a loss of $5.23. The revisions highlight continued heavy losses and delayed profitability; FY2030 was modestly improved to a $1.48 loss. HC Wainwright earnings estimate revisions
Beam Therapeutics Company Profile
(
Get Free Report)
Beam Therapeutics Inc is a biotechnology company developing precision genetic medicines for patients with serious diseases. The company's platform uses base editing, a form of gene editing designed to make targeted changes to individual DNA letters without creating double-strand breaks. Beam is also advancing related editing technologies and delivery systems intended to improve the precision and effectiveness of genetic treatments.
Beam's pipeline includes investigational programs for diseases such as sickle cell disease, beta thalassemia, alpha-1 antitrypsin deficiency and glycogen storage disease type Ia.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Beam Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beam Therapeutics wasn't on the list.
While Beam Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.